RLMD
Relmada Therapeutics, Inc.
There isn't enough reported data to score RLMD yet.
RLMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RLMD's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
RLMD PE Valuation
RLMD has no meaningful PE right now: it lost money over the past year.
RLMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect RLMD's earnings, revenue and profitability to hold roughly steady.
RLMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.72 | +$1.08 |
| Q2 2026 | -$0.90 | +$1.32 |
| Q1 2026 | -$1.09 | +$1.42 |
| Q4 2025 | -$1.45 | +$1.20 |
| Q3 2025 | -$1.80 | +$1.07 |
| Q2 2025 | -$2.22 | +$1.24 |
| Q1 2025 | -$2.51 | +$1.20 |
| Q4 2024 | -$2.65 | +$1.22 |
RLMD is still losing money, but far less than before: $0.72 per share over the past year, against $7.22 at its worst in early 2022.
RLMD Quarterly Revenue
RLMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12.6M | -$5.9M |
| Q2 2026 | -$9.6M | -$3.2M |
| Q1 2026 | -$15.1M | +$3M |
| Q4 2025 | -$14.6M | -$5.8M |
| Q3 2025 | -$6.7M | +$9.9M |
| Q2 2025 | -$6.4M | +$6.9M |
| Q1 2025 | -$18.1M | -$5M |
| Q4 2024 | -$8.8M | +$1.5M |
RLMD has burned cash in almost every quarter: −$52M over the past year, against −$40M the year before.
RLMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +61.8K shares |
| 1 year | +239% | +79.2M shares |
| 3 years | +274% | +82.3M shares |
| 5 years | +578% | +95.9M shares |
| Available history | +889% | +101M shares |
RLMD has 112M diluted shares, up 239% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $6.5M |
| Q1 2026 | $3.4M |
| Q4 2019 | — |
RLMD Net Leverage
RLMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RLMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.2 | Neutral |
| Stochastic | 36.8 | Neutral |
RLMD's weekly RSI is 45 (neutral) and its Stochastic is 37 (neutral).
RLMD PE vs Healthcare Sector
RLMD has no meaningful PE right now: it lost money over the past year.
RLMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.60 | 16% above |
| 20 week MA | $4.45 | 6.5% below |
| 50 week MA | $5.13 | 19% below |
| 100 week MA | $3.07 | 36% above |
| 200 week MA | $3.19 | 30% above |
RLMD's trend is mixed: it's above three of its five weekly moving averages, and 30% above its 200-week average.
RLMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $39.1 | $32.1 | -18% |
| 2021 | $32.1 | $22.3 | -31% |
| 2022 | $22.3 | $3.01 | -86% |
| 2023 | $3.01 | $4.12 | +37% |
| 2024 | $4.12 | $0.38 | -91% |
| 2025 | $0.38 | $4.51 | +1087% |
| 2026 YTD | $4.51 | $4.16 | -7.8% |
RLMD's yearly returns have swung widely, from +1087% in 2025 to −91% in 2024. It's down 7.8% so far in 2026.